Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06835426 | High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins | recruiting | N/A | 150 | Algemeen Ziekenhuis Maria MiddelaresOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 |
| clinicaltrials |
| NCT04731558 | Pre- Vs Postoperative Thromboprophylaxis for Liver Resection(PREPOSTEROUS) | recruiting | Phase 4 | 1,012 | Helsinki University Central HospitalOTHER | 2 | Feb 14, 2025 | clinicaltrials |
| NCT06827639 | In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients(FUTURE) | not yet recruiting | — | 640 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06821958 | Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF) | recruiting | N/A | 36 | Charite University, Berlin, GermanyOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823050 | A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | not yet recruiting | — | 59 | Xuhua DuanOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence(GOT) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | recruiting | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | recruiting | N/A | 234 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05532059 | Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05596630 | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC | recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06139042 | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers | recruiting | — | 1,608 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06542796 | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma | recruiting | N/A | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06818773 | Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer | not yet recruiting | Phase 4 | 35 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Feb 10, 2025 | clinicaltrials |
| NCT06813508 | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH(BOMASH) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06718257 | Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma | recruiting | — | 300 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06806579 | Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma(ARTE) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06651346 | Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples | not yet recruiting | — | 100 | University of VirginiaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798194 | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma | not yet recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03695952 | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04308174 | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer(DEBATE) | active not recruiting | Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05222971 | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy(OPTIMUM) | recruiting | Phase 2 | 62 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06707233 | Y-90 SIRT for Unresectable HCC Larger Than 7cm | recruiting | Phase 2 | 33 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06792097 | Ga-68 Dolacga PET Scan in HCC Under RFA(HCC; RFA) | not yet recruiting | — | 10 | National Taiwan University HospitalOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06788353 | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05932836 | An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC | active not recruiting | — | 165 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06334965 | Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort(OPERANDI-HCC) | recruiting | N/A | 180 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06781242 | Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis | recruiting | — | 300 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06607276 | Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777628 | Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma(Immunecheck) | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777914 | Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers | recruiting | — | 600 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777017 | Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?(ELASTORFA) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06774768 | Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients(DARE) | not yet recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06622031 | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT | recruiting | N/A | 42 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06664021 | Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06767579 | Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation | recruiting | — | 350 | Yonsei UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04615143 | Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC(TALENT) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06766643 | Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762782 | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery | recruiting | Phase 2 | 276 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | recruiting | Phase 3 | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 6 | Jan 7, 2025 | clinicaltrials |
| NCT04295317 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery | active not recruiting | Phase 2 | 65 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | recruiting | Phase 3 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2025source: clinicaltrials